MedTrace Logo

Cenobamate in Adults With Focal-Onset Seizures

NCT05859854 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 936

Last updated 2025-09-08

No results posted yet for this study

Summary

The BLESS Study contributes to filling this information gap by collecting data from the Italian clinical practice and the Compassionate Use Program, to better characterize the clinical profile of cenobamate describing its effectiveness, safety and tolerability in adult patients diagnosed with uncontrolled focal epilepsy despite the use of at least two antiepileptic medicinal products.

Conditions

  • Epilepsy
  • Focal-Onset Seizure
  • Neurological Disorder

Sponsors & Collaborators

  • Iqvia Pty Ltd

    collaborator INDUSTRY

  • Aziende Chimiche Riunite Angelini Francesco S.p.A

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-24
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05859854 on ClinicalTrials.gov